Executive Summary

LONDON, May 13, 2026 — The biotech industry is poised for transformative growth with an estimated market size of $1.77 trillion in 2025, projected to reach $5.71 trillion by 2034 according to Precedence Research. Key players such as Trinity Biotech, NG Biotech, and Inscripta are making significant strides with innovations like AI-native platforms, rapid diagnostic tests, and genome editing technologies. The convergence of artificial intelligence and biotechnology promises to accelerate scientific discovery and improve healthcare outcomes, while Pittsburgh emerges as a burgeoning biotech hub attracting federal investment and spearheading innovation.

Established Players or Research Landscape

Trinity Biotech plc has introduced the CGM+ system, a continuous glucose monitoring platform integrated with artificial intelligence, which targets the substantial $260 billion AI wearable market. NG Biotech has received the FDA Breakthrough Device Designation for its NG-TEST® products, focusing on rapid diagnostics for infectious diseases such as Candida auris and Acinetobacter. These technologies highlight a broader trend of leveraging digital tools for real-time health data analytics and precise diagnostics.

Inscripta's Onyx platform offers fully automated benchtop genome editing, marking a significant leap in CRISPR technology applications in biological research and therapeutic development. Meanwhile, Caribou Biosciences continues to drive forward the use of CRISPR in developing cell therapies, further advancing possibilities in personalised medicine. As technologies such as bioprinting and advanced biomaterials emerge, companies like NanoSpun Technologies and Bioramics are paving the way with new biomedical applications.

Key Players in Biotech Innovations

Technologies or Forces Driving the Trend

The biotechnology sector has embraced artificial intelligence as a cornerstone of innovation, facilitating advancements in healthcare analytics, drug discovery, and patient management systems. For more on [related biotech developments](/top-10-ai-drug-discovery-startups-to-watch-in-2026-innovations-from-uk-us-canada-germany-italy-france-japan-china-israel-and-singapore-03-12-2025). As detailed in Axios, AI-driven scientific innovations are enhancing experiment design and data analysis, significantly impacting fields like robotics and environmental science. This integration of AI into biotechnology is streamlining processes, improving accuracies in predictive diagnostics, and crafting personalised medicine solutions.

Moreover, the rise of rapid diagnostic technologies, such as those from NG Biotech, underscores an era where early disease detection and targeted therapies are becoming the norm rather than the exception. Additionally, genome editing technologies led by Inscripta and Caribou Biosciences are broadening the horizons of genetic research, offering new methods to tackle genetic disorders and cancer therapies. Such innovations reflect a shift toward more precise and efficient biotech applications, harnessing the power of AI for optimised health outcomes.

Market or Industry Implications

The biotech sector's growth is driven by significant investment inflows as highlighted in a January 2026 Axios report noting a surge in biotech dealmaking. Investors are increasingly focusing on breakthrough technologies such as CRISPR, AI-in-healthcare, and biomanufacturing, forecasting robust activity in IPOs and M&As. Companies like Trinity Biotech stand to gain considerably as AI-native systems capture large market shares.

Pittsburgh's emergence as a pivotal biotech hub, bolstered by academic institutions and startup ecosystems, signifies how regional centres can attract core biotech projects. With federal investments channelled into local initiatives, new companies are spurred to innovate in diagnostics and therapies, diversifying and enriching the biotech landscape. The emphasis on biotechnological applications in healthcare and sustainable practices indicates a future where biotech could address global challenges from healthcare to environmental sustainability.

Biotech Market Statistics – 2024–2026 Forecasts

What Comes Next (12–36 months outlook)

Over the next few years, we anticipate increased reliance on AI tools in biotechnology to enhance precision medicine and drive breakthroughs in therapeutic strategies. The global biotech sector is expected to maintain a compound annual growth rate of 12.5% through 2034, according to Precedence Research. This vigorous growth trajectory will continue to be fuelled by venture capital, institutional investments, and policy support.

However, projections carry uncertainty and depend on market conditions and regulatory environments. The alignment of public health goals and technological advancements will be crucial in determining how and where the sector expands. We expect that companies making strides in AI integration and rapid diagnostics will be at the forefront of innovation, exemplifying the interconnectedness of technology and human health.

References

1. Axios. (2026, February 19). How Pittsburgh can cash in on biotech boom. Axios
2. Axios. (2026, January 12). There's a biotech boom in dealmaking. Axios
3. Axios. (2025, December 31). 2025's AI-fueled scientific breakthroughs. Axios
4. Trinity Biotech. (2025). Trinity Biotech unveils CGM+ AI-native platform. NASDAQ
5. NG Biotech. (2025). FDA Breakthrough Device Designation. NG Biotech